Parnax Lab (BOM:506128) Cyclically Adjusted Revenue per Share: ₹184.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506128 Parnax Lab Ltd BOM:506128
70 GF Score
Price ₹122.00
GF Value ₹148.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Parnax Lab Cyclically Adjusted Revenue per Share?

Parnax Lab BOM:506128 -0.45% 70 Cyclically Adjusted Revenue per Share is ₹184.03 as of Jun. 2026. GuruFocus rates BOM:506128 with a GF Score™ of 70/100 and a GF Value™ of ₹148.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Parnax Lab's adjusted revenue per share for the three months ended in Jun. 2026 was ₹49.455. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹184.03 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Parnax Lab's average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Parnax Lab was 8.20% per year. The lowest was 5.10% per year. And the median was 5.40% per year.

As of today (2026-08-28), Parnax Lab's current stock price is ₹122.00. Parnax Lab's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹184.03. Parnax Lab's Cyclically Adjusted PS Ratio of today is 0.66.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Parnax Lab was 1.11. The lowest was 0.15. And the median was 0.60.


Parnax Lab  (BOM:506128) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Parnax Lab's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=122.00/184.03
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Parnax Lab was 1.11. The lowest was 0.15. And the median was 0.60.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Parnax Lab Cyclically Adjusted Revenue per Share Related Terms


Parnax Lab Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Parnax Lab's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parnax Lab Cyclically Adjusted Revenue per Share Chart

Parnax Lab Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 141.50 153.51 162.92 164.35 179.75

Parnax Lab Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.25 172.85 176.16 179.75 184.03

BOM:506128 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parnax Lab's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnax Lab Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnax Lab's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Parnax Lab's Cyclically Adjusted PS Ratio falls into.


BOM:506128
70GF Score
Parnax Lab Ltd BOM:506128
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parnax Lab Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Parnax Lab's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=49.455/167.3573*167.3573
=49.455

Current CPI (Jun. 2026) = 167.3573.

Parnax Lab Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 29.546 105.961 46.666
201612 31.373 105.196 49.912
201703 25.109 105.196 39.946
201706 26.925 107.109 42.070
201709 41.865 109.021 64.266
201712 29.555 109.404 45.211
201803 25.222 109.786 38.448
201806 27.269 111.317 40.997
201809 49.757 115.142 72.321
201812 27.618 115.142 40.142
201903 23.515 118.202 33.294
201906 25.545 120.880 35.367
201909 30.222 123.175 41.062
201912 30.008 126.235 39.783
202003 27.761 124.705 37.256
202006 20.401 127.000 26.884
202009 31.496 130.118 40.510
202012 29.190 130.889 37.323
202103 24.717 131.771 31.392
202106 33.862 134.084 42.265
202109 42.120 135.847 51.890
202112 59.787 138.161 72.421
202203 55.822 138.822 67.296
202206 37.512 142.347 44.103
202209 37.610 144.661 43.511
202212 43.985 145.763 50.501
202303 33.075 146.865 37.690
202306 42.547 150.280 47.382
202309 37.160 151.492 41.052
202312 44.512 152.924 48.713
202403 40.091 153.035 43.843
202406 43.689 155.789 46.933
202409 42.146 157.882 44.675
202412 35.225 158.323 37.235
202503 42.828 157.552 45.494
202506 46.539 159.755 48.754
202509 54.332 162.289 56.029
202512 54.952 163.281 56.324
202603 60.782 164.272 61.923
202606 49.455 167.357 49.455

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹184.03 mean?
Parnax Lab (BOM:506128) has a Cyclically Adjusted Revenue per Share of ₹184.03 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Parnax Lab and its competitors.
Is Parnax Lab's Cyclically Adjusted Revenue per Share too high?
Parnax Lab's current Cyclically Adjusted Revenue per Share is ₹184.03. Overall, Parnax Lab has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Parnax Lab's Cyclically Adjusted Revenue per Share compare to ZTS?
Parnax Lab's Cyclically Adjusted Revenue per Share of ₹184.03 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Parnax Lab and its competitors. Parnax Lab's current Cyclically Adjusted Revenue per Share is ₹184.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parnax Lab stock overvalued right now?
Based on GuruFocus' analysis, Parnax Lab (BOM:506128) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹148.17, compared to a current price of ₹122.00 — trading 17.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹184.03. Parnax Lab's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Parnax Lab (BOM:506128), the current Cyclically Adjusted Revenue per Share is ₹184.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Parnax Lab (BOM:506128) Overvalued in 2026?

Based on GuruFocus' analysis, Parnax Lab stock appears to be undervalued. The current stock price of ₹122.00 is trading 17.7% below its estimated GF Value™ of ₹148.17. GuruFocus considers Parnax Lab to be Modestly Undervalued.

Key valuation signals for BOM:506128:

  • Cyclically Adjusted Revenue per Share: ₹184.03
  • GF Value™: ₹148.17 vs. price of ₹122.00 (17.7% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the BOM:506128 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Parnax Lab Business Description

Other Exchanges PARNAXLAB:India
Address 104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.
70GF Score

Get the complete analysis for BOM:506128

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹122.00
Price
₹148.17
GF Value